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Abstract
We, and others, have suggested that as the SARS-CoV-2 virus may modulate mitochondrial function, good
mitochondrial reserve and health could be key in determining disease severity when exposed to this virus, as the
immune system itself is dependent on this organelle’s function. With the recent publication of a paper showing
that long COVID could be associated with the reactivation of the Epstein Barr Virus, which is well known to
manipulate mitochondria, we suggest that this could represent a second mitochondrial “whammy” that might
support the mitochondrial hypothesis underlying COVID-19 severity and potentially, the occurrence of longer-term
symptoms. As mitochondrial function declines with age, this could be an important factor in why older populations
are more susceptible. Key factors which ensure optimal mitochondrial health are generally those that ensure
healthy ageing, such as a good lifestyle with plenty of physical activity. The ability of viruses to manipulate
mitochondrial function is well described, and it is now also thought that for evolutionary reasons, they also
manipulate the ageing process. Given that slowing the ageing process could well be linked to better economic
outcomes, the link between mitochondrial health, economics, COVID-19 and other viruses, as well as lifestyle, needs
to be considered.
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Background
As mitochondria are key in the immune response [1], we
have previously suggested that as SARS-CoV-2 may
modulate mitochondrial function it may have a greater
adverse effect in those with poorer mitochondrial health,
such as the elderly and those displaying evidence of the
metabolic syndrome [2]. We are not alone in this think-
ing [3–5], which is why it has been suggested that high
aerobic fitness could be beneficial [6]. In fact, data con-
tinue to support a role for mitochondrial dysfunction
and metabolic perturbation in the pathogenesis of this
condition [7, 8] – including coincident hyperglycaemia
that seems to be associated with more severe disease [9].
In short, good mitochondrial health and reserve could
well be important components in the resistance to
SARS-CoV-2. Although there is building evidence for
this [10], the idea is still not yet mainstream.
However, it now seems that “long COVID” could also
be related to reactivation of the Epstein Barr Virus
(EBV), which lies dormant in a very high percentage of
the population [11]. For instance, there is a correlation
with impaired lymphocyte subpopulation count, EBV
load and severity of disease [12], as well as evidence that
EBV can induce angiotensin-converting enzyme 2
(ACE2) expression and SARS-CoV-2 entry to epithelial
cells [13]. Critically, given that more than half of survi-
vors of COVID-19 appear to have long term symptoms
(post-acute sequelae of COVID-19 [PASC]) or “long-
COVID” [14], the described association of EBV with
mitochondrial dysfunction [15] could play a key role in
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susceptibility and recovery from SARS-CoV-2. Further-
more, the recent discovery that mitochondrial function
is essential for sustained killing by cytotoxic T cells, for
instance, of virally infected cells [16], is perhaps also
suggestive, as EBV can also infect T cells [17]. In this
regard, it is perhaps relevant that in people with SARS-
COV-2 a subset of T cells with an altered metabolic
profile, which are prone to mitochondrial apoptosis and
resultant lymphopenia, as well as enhanced numbers of
myeloid-derived suppressor cells, are associated with dis-
ease severity and altered voltage dependent anion chan-
nel 1 (VDAC1) expression – a pivotal mitochondrial
protein [18].
In effect, EBV could tip an already compromised sys-
tem into a self-perpetuating metabolic-oxidative stress-
inflammatory spiral that could underly many of the
symptoms of long COVID. The likelihood of this hap-
pening could be increased in people who already have
sub-optimal mitochondrial function associated with a
sedentary lifestyle. In this regard, a genetic and pheno-
typic analysis of the causal relationship between ageing
and COVID-19 seems to indicate that accelerated bio-
logical ageing is a key factor in susceptibility risk, with
both altered Notch signalling and B cell functioning be-
ing important [19].
EBV modulates mitochondria – a second whammy?
The association between EBV-induced chronic fatigue
syndrome with mitochondrial dysfunction was suggested
many years ago [15]. EBV can alter mitochondrial dy-
namics and DNA replication [20, 21], as well as interact
with latent membrane protein 1 (LMP1) and dynamin-
related protein 1 (Drp1), enhancing glycolysis [22]. It
can also induce metabolic reprogramming in monocytes,
which is associated with decreased autophagy and mito-
chondrial biogenesis. This enhances apoptosis and
reduces immune surveillance [23]. EBV also modulates
c-Myc activity and glutaminolysis and thus aerobic
glycolysis and enhances the activity of glutaminase-1
(GLS-1) isoforms in mitochondria, which explains its as-
sociation with cancer [24]. This therefore raises the pos-
sibility that reactivation of the EBV serves as a second
mitochondrial “whammy”, leading to a sustained inflam-
matory response and the classical symptoms of brain
fog, tiredness and weakness. This has many similarities
to cytokine induced sickness behaviour associated with
other conditions, such as cancer, cancer treatment, mul-
tiple sclerosis, as well as virally-induced fatigue syn-
drome, where mitochondrial dysfunction could also play
a role [25]. The key here is that dysfunctional mitochon-
dria can be a source of oxidative stress, which in turn,
further compromises mitochondrial recovery due to
feedback and their role in inflammatory signalling [26].
It is thus possible that even if the cause of the first
whammy, the corona virus, is cleared, this imbalance
can continue for some time; the second EBV whammy,
whether coincident, or caused by reactivation due to re-
duced immune function, would only make this worse.
Mitochondria are more than just “powerhouses”
of the cell
At the most basic level the mitochondrion must bal-
ance metabolic priorities between energy production,
growth, defence and the management of oxidative
stress. The key to understanding this is that mitochon-
dria are not just “powerhouses”, but also sense the cel-
lular environment, control growth, inflammation,
senescence and death. Having a good mitochondrial re-
serve enables the cell to be flexible and multi-task,
whether it is in a neuron or an immune cell; loss of this
flexibility certainly plays a role in ageing-related immu-
nosenescence and the concept of “inflammaging” [27].
This is why physical activity is generally viewed as be-
ing a very good medicine, as all mitochondria in the
body communicate with each other via myokines; the
stress of exercise doesn’t just induce an adaption in
muscle, but in all other bodily systems and improves
overall robustness [28]. This perhaps reflects our evolu-
tionary heritage where movement was normal and be-
came canalised as a necessary factor to maintain fitness
in a calorie restricted environment; not moving and
eating too much thus takes humans outside our evolu-
tionary “flight envelope” [29].
Long COVID is not just a sequalae of the very ill
It may well be relevant that pathogens such as viruses
appear to manipulate the ageing process for their own
evolutionary benefits, which could be viewed as an ex-
tension of the disposable soma theory of ageing [30].
This might suggest that even in people who do not ex-
hibit particularly severe symptoms with the initial SARS-
CoV-2 infection, reactivation of EBV, or other viruses,
could trigger a secondary longer-term syndrome if their
mitochondrial reserve is low. In terms of prevention and
treatment, not only would this continue to support phys-
ical activity as being key, but also diets high in plant de-
fence compounds with pleiotropic actions that are
known to modulate mitochondrial function, induce reso-
lution of inflammation, as well as displaying anti-
pathogen function. This concept could also extend to
existing drugs that also have pleiotropic actions involv-
ing modulation of mitochondrial function, such as met-
formin or steroids. It might also hint that mild calorie
restriction, which can enhance mitochondrial function
and reduce inflammation, could also play a role [2]. It
has also been suggested a ketogenic diet might help, as
mitochondria are key in the metabolic adaptation [31].
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Viral reactivation might also indicate why there is
some variability in response to treatment, as it is pos-
sible that each patient could have a mix of reactivated
viruses, or other pathogens that complicate interpret-
ation of efficacy as their bodies try to balance the
multiple functions of mitochondria. A case in point is
the potential for gut microbiota to affect how appar-
ently healthy subjects respond to COVID-19 [32] and
that there is cross-talk between gut microbiota and
mitochondria, for instance, after exercise [33]. In
short, having a healthy mitochondrial system could
prevent a “domino” effect leading to a tipping point
into a chronic inflammatory state, and if already in-
fected, mitochondrial support and protection may
provide a means to break the cycle. It therefore con-
tinues to suggest that not getting the virus in the first
place, or being vaccinated, are key strategies. Indeed,
a study in Switzerland suggested that 34.8 % of partic-
ipants in an outpatient setting had post-acute symp-
toms seven months after diagnosis of COVID-19 [34].
Conclusions – the cost of mitochondrial ill-health
As is fairly well established, a poor lifestyle accelerates
the ageing process leading to morbidity expansion [29],
which reduces the capacity of an individual to work and
increases the load on society [35]. Add to this that vi-
ruses may also influence the ageing process [30], then a
poor lifestyle coupled with increased viral load is going
to further accelerate ageing across society and negatively
affect the economy. Indeed a recent analysis suggests
that slowing ageing across society could be, by far, the
most sensible thing to do economically [36]. Given the
well described link between mitochondrial function and
ageing, especially of the immune system [37], then it
could be argued there is also one between economics
and mitochondrial health. Hence, the paper by Gold
et al.[11] hints at another very important angle that gov-
ernments, and healthcare providers, may need to con-
sider: overloading ill-prepared mitochondria could cost
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